GlassScriptPhysician profile
Leslie Carroll
NPI 1255994166
$4,462.85
in general payments reported to CMS, 2019-2025
36 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,008 · 2022: $1,282 · 2023: $1,729 · 2024: $292 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.58 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $745.15 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $292.98 | 2021 | |
| Amneal Pharmaceuticals LLC | $286.18 | 2021-2023 | Rytary |
| Pfizer INC. | $203.78 | 2023 | |
| Alexion Pharmaceuticals, INC. | $175.44 | 2021-2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $132.01 | 2021-2022 | |
| Daiichi Sankyo INC. | $123.07 | 2022 | |
| Amgen INC. | $107.77 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $107.54 | 2023 | Exparel |
| Biogen, INC. | $102.62 | 2021-2023 | Tysabri, Skyclarys |
| Lundbeck LLC | $96.12 | 2022-2023 | Vyepti |
| Celgene Corporation | $91.04 | 2023-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $78.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $73.97 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.44 | 2023 | Rexulti, Nuedexta |
| Allergan, INC. | $59.17 | 2021-2022 | |
| Lilly USA, LLC | $53.84 | 2021-2022 | |
| Sk Life Science, INC. | $52.91 | 2023 | |
| Ucb, INC. | $48.08 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.62 | 2022 | |
| Adamas Pharmaceuticals, INC. | $38.24 | 2021 | |
| Nevro Corp. | $33.84 | 2023 | Senza |
| Genentech USA, INC. | $33.25 | 2022-2023 | Ocrevus |
| Neurocrine Biosciences, INC. | $29.83 | 2022-2023 | Ingrezza, Ongentys |
| Argenx US, INC. | $28.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.71 | 2023 | |
| Genzyme Corporation | $23.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.83 | 2021 | |
| Horizon Therapeutics Plc | $22.56 | 2023 | Uplizna |
| Grt US Holding, INC. | $22.18 | 2021 | |
| Avion Pharmaceuticals | $19.90 | 2022 | |
| Acadia Pharmaceuticals INC | $13.79 | 2021 | |
| Tanabe Pharma America, INC. | $13.36 | 2022 | |
| Banner Life Sciences, LLC | $12.18 | 2022 | |
| Eisai INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.